Jazz Pharmaceuticals Highlights New Epidiolex Data in Treatment-Resistant Epilepsies at AES 2025
Jazz Pharmaceuticals plc announced that eight abstracts, including four late-breaking presentations, will be featured at the upcoming American Epilepsy Society $(AES)$ 2025 Annual Meeting, scheduled for December 5-9, 2025, in Atlanta, Georgia. The presentations will focus on new data and real-world evidence related to Epidiolex® (cannabidiol) for treatment-resistant epilepsies. Notably, interim results from the EpiCom trial, which evaluated behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes. Additional real-world studies using data from the U.S. Optum® Market Clarity Database indicate that Epidiolex initiation in cannabidiol-naïve patients with Dravet Syndrome, Lennox-Gastaut Syndrome, or tuberous sclerosis complex is associated with reduced polypharmacy and healthcare resource utilization at 12 months, with further reductions observed among early-line initiators. All results are scheduled to be presented at the AES 2025 Annual Meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF39931) on December 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.